These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

827 related items for PubMed ID: 19222457

  • 21. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion.
    Assaf C, Bagot M, Dummer R, Duvic M, Gniadecki R, Knobler R, Ranki A, Schwandt P, Whittaker S.
    Br J Dermatol; 2006 Aug; 155(2):261-6. PubMed ID: 16882161
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and Sézary syndrome.
    Tsirigotis P, Pappa V, Papageorgiou S, Kapsimali V, Giannopoulou V, Kaitsa I, Girkas K, Papageorgiou E, Stavrianeas N, Economopoulos T, Dervenoulas J.
    Br J Dermatol; 2007 Jun; 156(6):1379-81. PubMed ID: 17459033
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland.
    Väkevä L, Ranki A, Hahtola S.
    Acta Derm Venereol; 2012 May; 92(3):258-63. PubMed ID: 22678563
    [Abstract] [Full Text] [Related]

  • 27. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms.
    McGinnis KS, Junkins-Hopkins JM, Crawford G, Shapiro M, Rook AH, Vittorio CC.
    J Am Acad Dermatol; 2004 Mar; 50(3):375-9. PubMed ID: 14988678
    [Abstract] [Full Text] [Related]

  • 28. Results of a prospective phase II trial with oral low-dose bexarotene plus photochemotherapy (PUVA) in refractory and/or relapsed patients with mycosis fungoides.
    Rupoli S, Canafoglia L, Goteri G, Leoni P, Brandozzi G, Federici I, Micucci G, Giantomassi F, Mozzicafreddo G, Alterini R, Filosa G, Ricotti G, Simonacci M, Scortechini AR, Zizzi A, Pimpinelli N.
    Eur J Dermatol; 2016 Mar; 26(1):13-20. PubMed ID: 26678311
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. The optimal use of bexarotene in cutaneous T-cell lymphoma.
    Gniadecki R, Assaf C, Bagot M, Dummer R, Duvic M, Knobler R, Ranki A, Schwandt P, Whittaker S.
    Br J Dermatol; 2007 Sep; 157(3):433-40. PubMed ID: 17553039
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Palliative total skin electron beam therapy (TSEBT) for advanced cutaneous T-cell lymphoma.
    Funk A, Hensley F, Krempien R, Neuhof D, Van Kampen M, Treiber M, Roeder F, Timke C, Herfarth K, Helmbold P, Debus J, Bischof M.
    Eur J Dermatol; 2008 Sep; 18(3):308-12. PubMed ID: 18474461
    [Abstract] [Full Text] [Related]

  • 33. Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma.
    McGinnis KS, Shapiro M, Vittorio CC, Rook AH, Junkins-Hopkins JM.
    Arch Dermatol; 2003 Jun; 139(6):771-5. PubMed ID: 12810509
    [Abstract] [Full Text] [Related]

  • 34. Development of Hodgkin's lymphoma under bexarotene treatment for Sézary syndrome and review of the literature.
    Sanli H, Akay BN, Ozcan M.
    J Drugs Dermatol; 2010 Aug; 9(8):1014-6. PubMed ID: 20684154
    [Abstract] [Full Text] [Related]

  • 35. Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides.
    Papadavid E, Antoniou C, Nikolaou V, Siakantaris M, Vassilakopoulos TP, Stratigos A, Stavrianeas N, Katsambas A.
    Am J Clin Dermatol; 2008 Aug; 9(3):169-73. PubMed ID: 18429646
    [Abstract] [Full Text] [Related]

  • 36. Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies.
    Govindan R, Crowley J, Schwartzberg L, Kennedy P, Williams C, Ekstrand B, Sandler A, Jaunakais D, Bolejack V, Ghalie R.
    J Clin Oncol; 2006 Oct 20; 24(30):4848-54. PubMed ID: 17050870
    [Abstract] [Full Text] [Related]

  • 37. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides).
    Kessler JF, Jones SE, Levine N, Lynch PJ, Booth AR, Meyskens FL.
    Arch Dermatol; 1987 Feb 20; 123(2):201-4. PubMed ID: 2949706
    [Abstract] [Full Text] [Related]

  • 38. Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer.
    Ho AD, Suciu S, Stryckmans P, De Cataldo F, Willemze R, Thaler J, Peetermans M, Döhner H, Solbu G, Dardenne M, Zittoun R.
    Semin Oncol; 2000 Apr 20; 27(2 Suppl 5):52-7. PubMed ID: 10877053
    [Abstract] [Full Text] [Related]

  • 39. Bexarotene gel: a new skin-directed treatment option for cutaneous T-cell lymphomas.
    Martin AG.
    J Drugs Dermatol; 2003 Apr 20; 2(2):155-67. PubMed ID: 12852367
    [Abstract] [Full Text] [Related]

  • 40. Folliculotropic mycosis fungoides responding to bexarotene gel.
    Walling HW, Swick BL, Gerami P, Scupham RK.
    J Drugs Dermatol; 2008 Feb 20; 7(2):169-71. PubMed ID: 18335654
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 42.